INTRODUCTION
Blood coagulation is a complex of reactions, which involves several enzymes, cofactor proteins, phospholipid surfaces and Ca2+ ions. This waterfall or cascade system is initiated upon exposure of blood to tissue factor or negatively charged surfaces. Then the intrinsic or the extrinsic pathway of coagulation are initiated, leading to the formation of thrombin and fibrin. This clotting cascade prevents excessive bleeding upon injury (Furie & Furie, 1988; Mann et al., 1988) . Another example of a cascade system is the complement system, which is composed of two pathways: the classical pathway and the alternative pathway (Lachmann & Hughes-Jones, 1985) . The classical pathway is activated by immune complexes and the alternative pathway by activating surfaces such as the surface of a micro-organism. One of the main functions of the complement system is the lysis of target cells (Muller-Eberhard & Miescher, 1985; Law & Reid, 1988) . In recent years most of the components of both systems have been purified and the molecular interactions that are required for the catalytic events that occur at each step of the cascades have been characterized. Although both cascade systems are composed of many different proteins, there are only few interactions known between them. In fact, the interaction between complement component C4, C4b-binding protein (C4BP) and protein S constitutes a unique link between the complement and coagulation systems (Fig. 1 ). This review deals with the structural and functional relationships of C4, C4BP and protein S, and their regulation. In addition, the short consensus repeat (SCR) domains of C4BP will be discussed in context of other SCRcontaining proteins. A SCR unit is approx. 60 amino acids long and demonstrates a typical consensus framework of conserved residues. The SCR unit can be defined as a single domain with a double-loop structure, formed by overlapping disulphide bonds.
THE PROTEIN C ANTICOAGULANT PATHWAY
In recent times it has been recognized that apart from extrinsic and intrinsic coagulation and fibrinolysis pathways (Furie & Furie, 1988; Mann et al., 1988) there is another pathway involved in the regulation of the coagulation process, the so-called protein C pathway. The first step in the pathway is the conversion of protein C into its active form by thrombin. For this process a cofactor on the endothelial cell is necessary: thrombomodulin a powerful inhibitor of the coagulation pathway, by inactivating coagulation factors Va (Kisiel et al., 1977; Comp & Esmon, 1979; Walker et al., 1979; Dahlback & Stenflo, 1980; Marlar et al., 1982; Nesheim et al., 1982; Suzuki et al., 1983a; de Waart et al., 1984) and Vllla (Vehar & Davie, 1980; Marlar et al., 1982; Fulcher et al., 1984; Eaton et al., 1986; Walker et al., 1987; Koedam et al., 1988) , whereas at the same time it stimulates fibrinolysis by inactivating the inhibitor of tissue plasminogen activator (Comp & Esmon, 1981; Sakata et al., 1985; van Hinsbergh et al., 1985) . The expression of the anticoagulant activity of APC requires the presence of calcium ions and membranes that contain negatively charged phospholipids. In the absence of lipids, proteolysis of either factor V or VIII by APC is very slow. Plasma contains a component that accelerates the inactivation of factor V and VIII by APC (Walker, 1980, 198 la; Walker et al., 1987; Koedam et al., 1988) . This cofactor activity was found to be associated with a vitamin K-dependent protein, which was arbitrarily named protein S (DiScipio & Davie, 1979; Stenflo & Johnsson, 1979) in reference to its first isolation in Seattle. Its effect was found to be dependent on the presence of membranes that contained negatively charged phospholipids (Walker, 1981a) . Functional as well as binding studies indicated that protein S and APC were capable of forming a 1: 1 molar complex on the surface of phospholipid vesicles (Walker, 1981a) . However, so far no direct complex formation between protein S and APC, in solution or on phospholipid surfaces, has been demonstrated. APC can be inactivated in plasma by at least two protease inhibitors, the protein C inhibitor (Suzuki et al., 1983b; Meijers et al., 1988a) and al-antitrypsin (Van de Meer et al., 1987; Heeb & Griffin, 1988; Meijers et al., 1988b) . The anticoagulant activity of protein C has physiological significance because persons with severe protein C (or protein S) deficiency tend to have thrombosis (Griffin et al., 1981; Bertina et al., 1982; Esmon, 1984; Comp & Esmon, 1984; Schwarz et al., 1984; Bertina, 1985; Kamiya et al., 1986 Fig. 1 . Schematic illustration of a unique link between coagulation and the complement system Thrombin (T) binds to thrombomodulin (TM) expressed on endothelial cells and activates protein C (PC). Activated protein C (APC) requires a cofactor protein S (PS) for optimal interaction with endothelial cells or platelets and subsequent degradation of the activated procoagulant cofactors, FVa and FVIIIa, to the inactive forms, FVi and FVIIIi. PS can form a 1: 1 noncovalent complex with C4b-binding protein (C4BP), which is a cofactor for the inactivation of the C3-convertase (C4b2a) by factor I of the classical complement pathway. An interaction between Clq and immune complexes (Ag-Ab) is involved in the activation of the classical pathway, which triggers the activation of the other complement components C2, C4 and C3, leading to the polymerization of C5b-9 to form the membrane attack complex (MAC).
1977 ; Lundwall et al., 1986) . Table 1 lists the physical properties as well as the plasma concentration of protein S. Protein S serves as a cofactor in the inactivation of coagulation factor Va and VIIIa by activated protein C (APC) as described above. The protein S cofactor activity for APC is dependent on the presence of negatively charged phospholipids (Nelsetuen et al., 1978; Walker, 1981a) and is present on cell membranes, e.g. on the surface of platelets and endothelial cells (Walker, 1984a; Suzuki et al., 1984; Harris & Esmon, 1985; Stern et al., 1986a,b; Hessing et al., 1989; Hackeng et al., 1990) . For lipids to be effective, they 1991 C.T. OFTME (Ug/ml) must contain phosphatidylserine. The structure of the fatty acid side chains of the phospholipids and the presence of cholesterol in lipid vesicles influences the cofactor activity of protein S (Walker, 1988) . A new relationship between the anticoagulant protein C pathway and the autonomic nervous system has recently been suggested by the observation that noradrenalinemediated endothelial cell stimulation resulted in loss of intracellular protein S and suppression of cell surface binding sites, thus modulating the APC activity on the vessel wall (Brett et al., 1988) . Approximately half of the protein S in human plasma is present as a noncovalent complex (KD 10-v M) with complement component C4b-binding protein (C4BP), and the remaining half is present as a free protein (Dahlback & Stenflo, 1981) . The protein S-C4BP complex exhibited slow kinetics of association and dissociation (Dahlback, 1983b) . Only free protein S has cofactor activity for APC (Comp & Esmon, 1984 , 1986 Bertina et al., 1985; Dahlback, 1986) . The mechanism of the inhibition of the cofactor activity of protein S by C4BP is not clearly understood. However, ternary complex formation between protein S, C4BP and APC has now been demonstrated, suggesting that the protein S-C4BP complex competes with free protein S for binding to APC (Nishioka & Suzuki, 1990) . Protein S forms complexes with C4BP both in the presence of calcium (KD 5 x 10-10 M) and in the presence of EDTA (KD 10-7 M) (Dahlback, 1983b; Dahlback et al., 1990b Thrombin cleavage of protein S converts the single-chain protein to a disulphide-linked two-chain structure, which leads to decreased calcium and phospholipid binding and a parallel loss of the cofactor activity for APC (Dahlback, 1983a; Suzuki et al., 1983c; Walker, 1984b; Morita et al., 1986; Dahlback et al., 1986b) . The thrombin-mediated cleavage of protein S is inhibited by physiological calcium concentrations (Morita et al., 1986; Mitchell et al., 1986) . At high calcium concentrations (5-10 mM) both native protein S and protein S cleaved by thrombin bind equally well to phospholipids (Schwalbe et al., 1990) . The thrombin cleavage sites in bovine protein S are localized at Arg52 and Arg70 (Dahlback et al., 1986b) Modified from Lundwall et al. (1986) . bovine protein S demonstrate that, unlike the other vitamin Kdependent coagulation factors, protein S is not a serine protease (Dahlback et al., 1986a; Lundwall et al., 1986; Hoskins et al., 1987; . Protein S is composed of discrete domains and contains several functionally important post-translationally modified amino acids (Dahlback et al., 1986a; Stenflo et al., 1987) . Like the other vitamin K-dependent proteins ( Fig. 2a) , protein S contains a Gla-rich N-terminal region, which is terminated by a short hydrophobic region containing four aromatic residues, the so-called aromatic stack or H region (Park & Tulinsky, 1986) . This is followed by a thrombin-sensitive region and four epidermal growth factor (EGF) homologous regions (Doolittle et al., 1984) , containing one fl-hydroxyaspartic acid residue and three ,-hydroxyasparagine residues each. /J-Hydroxyaspartic acid was first recognized in protein C (Drakenberg et al., 1983) and factor X (McMullen et al., 1983a,b) , whereas ,1-hydroxyasparagines were first found in protein S. The functions of these amino acid residues are not yet elucidated, but it has been suggested that they are important for Gla-independent high-affinity calcium binding (Sugo et al., 1986; Stenflo et al., 1987; Rees et al., 1988; Dahlback et al., 1990a) . At the C-terminus a 387-amino-acid domain of unrecognized structure and unknown function is present, which is partly similar to the sexual hormone binding globulin (SHBG), an androgen-binding protein in plasma (Baker et al., 1987; Gershagen et al., 1987) . Fig. 2(b) shows the tentative secondary structure and different domains of human protein S. The functional importance of the various regions in protein S is only partly established. The Gla region is required for calcium and phospholipid binding (Sugo et al., 1986; Furie & Furie, 1988; Dahlbdck et al., 1990a) . The EGF-like domains are suspected to contain the high-affinity Gla-independent binding sites, and a model in which APC and protein S interact via the first EGF-like domain and the thrombin-sensitive region has been proposed (Dahlback et al., 1990a) . No specific function has been assigned to the SHBG-like domain, although Walker (1989) has claimed that amino acids 605-614 of the protein S sequence are important for the interaction with C4BP.
Two genes homologous with the human protein S cDNA are located near the centromere on chromosome 3 (Ploos van Amstel etal., 1987 van Amstel etal., , 1988 van Amstel etal., , 1990 Watkinsetal., 1988; Longetal., 1988; Edenbrandt et al., 1990) . The protein S genes, PSa and PSfl, span approx. 1200 nucleotides and show a high degree (96.5 %) of similarity (Ploos van Amstel et al., 1988 between their exonic sequences. The protein S gene, PSa, contains 15 exons that code for proteins S mRNA as derived from the reported protein S cDNAs, whereas the PS,# gene was identified as a pseudogene (Long et al., 1988; Edenbrandt et al., 1990; Ploos van Amstel et al., 1990; Schmidel et al., 1990) . The intron-exon organization of the PSa gene is similar to that of the other coagulation factors, i.e. each exon codes for a separate domain in the protein. Recently, Malm et al. (1990) reported on the expression of completely y-carboxylated and f,-hydroxylated recombinant human protein S that had full biological activity as cofactor for APC and was able to bind to C4BP.
C4b-BINDING PROTEIN
C4b-binding protein (C4BP) (previously named C3b-C4bINA cofactor) is a high-M, plasma protein, which regulates the activation of the classical pathway of the complement system (Scharfstein et al., 1978; Fujita-et al., 1978; Gigli et al., 1979; Nussenzweig & Melton, 1981) . Table 1 lists the physical properties as well as the plasma concentration of C4BP. C4BP functions as a cofactor for factor I in the proteolytic degradation of C4b (Fujita et al., 1978; Gigli et al., 1979; Fujita & Tamura, 1983) and in addition accelerates the decay rate of the C4b2a (EC 3.4.21.43) complex (Gigli et al., 1979; Daha & van Es, 1980) . The mechanism by which the binding of C4b to C4BP turns C4b into a substrate for factor I is unknown, but presumably involves a conformational change in C4b (Fujita & Tamura, 1983) .
C4BP is present in human plasma in two major forms, antigenically identical, but of slightly different molecular mass (530 and 570 kDa) and net charge. Both forms (referred to as C4BP-high and C4BP-low) act as cofactors in the cleavage of C4b by factor I . C4BP-high is the dominant form and accounts for up to 80 % of C4BP in plasma (Dahlback, 1983b; Villiers et al., 1981) . The major form of C4BP (570 kDa) is composed of multiple identical a-chains of 70 kDa and one distinct fl-chain of 45 kDa that are linked via disulphide bridges (Scharfstein et al., 1978; Reid & Gagnon, 1982;  Hillarp & Dahlbdck, 1988 & Dahlbdck, , 1990 Hillarp et al., 1989; Hessing et al., 1990c) . Each of the a-chains forms a tentacle with the Nterminus located at the periphery of the tentacle, whereas the Ctermini are located in the central core of C4BP Nagasawa et al., 1983; Perkins et al., 1986) . Electron microscopic studies of C4BP have suggested that C4BP has a spider-like structure with seven elongated tentacles extending from a central, ring-like core (Dahlback et al., 1983; . Solution X-ray scattering studies suggested that C4BP in solution resembles a more rigid bundle of seven arms in contrast to the splayed-out images seen in electron micrographs (Perkins et al., 1986) . The binding sites for C4b are located at the peripheral half of each a-chain Fujita et al., 1985) and it has been reported that up to 4.8 molecules of C4b can bind to one C4BP molecule (Scharfstein et al., 1978) . It has recently been suggested that there are four strong (KD 0.8 x 10-7 M) and two weak sites for C4b on C4BP (Ziccardi et al., 1984) and the addition of more C4b molecules is sterically hindered. However, the absorption coefficient used for C4BP of 9.3 (Villiers et al., 1981) was lower than the one of 14.1 determined by Perkins et al. (1986) , and a new interpretation of the less-than-full binding of C4b to C4BP would lead to an increase in the number of C4b molecules that can bind to one single C4BP molecule, which would be in agreement with the results of a hydrodynamic analysis of the C4BP structure (Perkins et al., 1986) . The physiological concentration of C4BP exceeds the observed KD of the C4BP-C4b interaction, suggesting that any C4b molecule present in serum is bound to C4BP.
Limited proteolysis of C4BP by chymotrypsin results in the cleavage of two peptide bonds, at Tyr396 and Trp426, yielding two major fragments (Nagasawa et al., 1982) . Reid & Gagnon (1982) showed that trypsin selectively cleaves a peptide bond in the middle of each a-chain of C4BP, generating fragments of 36-39 kDa. These two fragments are disulphide-linked, in contrast with the chymotrypsin digestion. Limited digestions of human C4BP with chymotrypsin, trypsin and pepsin (Chung et al., 1985a) have indicated that the cofactor activity for factor I is located in the region of residues 177-322 and that the region 332-395 may be important for the binding to C4b (Chung & Reid, 1985) . The localization of the C4b-binding site to these regions in the middle of the a-chains is in disagreement with previous results obtained from electron microscopic studies of the C4BP-C4b complex , that demonstrated that C4b was bound to the N-terminal tips of the achains.
The complete amino acid sequence of one of the a-chains of C4BP was determined by a combination of cDNA and peptide sequencing (Chung et al., 1985a,b; Lintin & Reid, 1986 (1985) and Suzuki & Nishioka (1988) respectively, are indicated. More recently, it became obvious that the fl-chain is important for the binding of protein S (Hillarp & Dahlback, 1988; Hillarp et al., 1989; Hessing et al., 1990c ). a 5' cDNA clone for human C4BP was isolated and sequenced to complete the cDNA sequence coding for residues 1-32, thus confirming the protein sequence data. From this sequence a leader peptide sequence was derived, which was 32 residues in length and showed a high degree of hydrophobicity typical of documented leader sequences (Lintin etal., 1988) . Recently, Matsuguchi et al. (1989) isolated and analysed the cDNA for proline-rich protein and revealed that it is identical with that of the a-chain of C4BP. Proline-rich protein (Sata et al., 1976 ) is a glycoprotein present in chylomicrons with lipid binding properties, but with no clear function.
Recently, determined the primary structure of the f-chain of C4BP. The #-chain consisted of 235 amino acids and the calculated molecular mass was found to be 26.4 kDa, which was in contrast with the estimated mass of 45 kDa derived from gel electrophoresis. The difference was caused by glycosylation of the mature molecule. The f-chain can be divided into three SCRs, each of 57-60 residues in length with the typical pattern of conserved amino acids shared by all SCRcontaining proteins. As a consequence, the fl-chain of C4BP is similar to the a-chain of C4BP and in addition the C-terminal end of the f-chain is rather similar to the corresponding region of the a-chain. In 1981, Dahlback & Stenflo demonstrated the existence of the C4BP-protein S complex. Protein S and C4BP formed a 1: 1 non-covalent complex with an apparent KD of (1.6-4.5) x 10-7 M (Dahlback, 1984 effect on the C4b-binding function of C4BP (Dahlback & Hildebrand, 1983) . The protein S binding site on C4BP has been localized near the central core (Dahlback et al., 1983; Hillarp & Dahlbaick, 1987; Nukatsuka & Nagasawa, 1987; Suzuki & Nishioka, 1988) on the distinct disulphide-linked fl-chain (Hillarp & Dahlback, 1988 Hillarp et al., 1989; Hessing et al., 1990c ). The ,-chain was sensitive for proteolysis by chymotrypsin and when cleaved the protein S binding ability is lost. When occupied with protein S the ,8-chain was protected from cleavage by chymotrypsin (Hillarp & Dahlback, 1988) . In contrast, Suzuki & Nishioka (1988) localized the protein S binding site on C4BP at a 2.5 kDa peptide corresponding with Ser447-Tyr467 of each a-chain. This region is located in the most C-terminal unit of the eight SCRs of each a-chain of C4BP (Chung et al., 1985a,b) . In 1983, only C4BP-high was found to be able to bind protein S (Dahlback, 1983a) , but the interpretation of the complex formation between protein S and C4BP was somewhat complicated by the fact that there seemed to exist two different populations of C4BP, differing in protein S binding ability. At present, it has become clear that approx. 80% of C4BP in plasma can bind to barium citrate via its interaction with protein S and that both the adsorbed C4BP-high and -low form are able to bind protein S and contain the fl-chain. C4BP-high and -low forms isolated from the supernatant of barium citrate adsorbed plasma were incapable of binding protein S and were lacking the fl-chain (Hillarp et al., 1989; Hessing et al., 1990c . The SCR unit can be defined as a single domain with a double-loop structure, formed by overlapping disulphide bonds in a 1-3 and 2-4 fashion (Fig.  4) and is encoded by a single exon (Janatova et al., 1989; . Prediction ofthe secondary structure suggests that the SCR will take the form of a predominantly fl-structure and a model based on antiparallel fl-strands has been proposed (Perkins et al., 1988) . The presently available data suggest that proteins containing SCRs arranged in tandem have an elongated structure with compact SCR units resembling a long string of pearls . Such an elongated structure might be advantageous for receptor proteins like C4BP, factor H, CR1 and 2 to increase their action radius for their respective ligands. Janatova et al. (1989) have localized the disulphide bonds in one of the SCRs of C4BP, which indicated that the intra-SCR disulphides are linked with the first and third and the second and fourth half-cystine in one SCR unit. The same pattern has been found in f2-glycoprotein I, a non-complement protein containing five SCRs (Lozier et al., 1984) . So far, no inter-SCR disulphide bonds have been found in any of the SCR-containing proteins. This is consistent with the observations that most of the SCRs are encoded by separate exons Kristensen et al., 1987a) . However, some variation in the principle of one exon per SCR has been observed (Barnum et al., 1989) .
The function of the SCRs is not yet elucidated, but it is tempting to believe that they provide the structural basis for the C3b and C4b binding capacity. On the other hand, there are many proteins belonging to this superfamily of SCR-containing proteins that are not involved in complement (Table 2 ). Many of these proteins are able to bind other proteins, but the involvement of SCR in these interactions has not been clarified. It has been suggested that the SCRs may be utilized in a variety of binding reactions in a manner similar to the immunoglobulins, or that a SCR unit may be responsible for a certain overall structure of the SCR-containing proteins Kristensen et al., 1987a ).
The identification of the adhesion molecules ELAM-1, and GMP-140 suggested the existence of a new gene family of proteins that are involved in carbohydrate-dependent interaction between circulating blood cells and the endothelium. These adhesion proteins consist of domains homologous to the lectins, SCR and EGF and therefore this family has been named lectin-EGF-complement-cellular adhesion molecules (LEC-CAM) (Stoolman, 1989) . Also in this case is the function of the SCRs unknown, but they contain most or all of the invariant residues that constitute the consensus sequence of an SCR unit.
In addition, the first half of each repeat contains two extra conserved cysteines, indicating a strong relationship between these three adhesion proteins. The same structural motifs as occur in the LEC-CAM family have been found in the proteoglycan versican (Zimmermann & Ruoslahti, 1989) . Several other proteoglycans from various species contain lectins and SCRs, but these SCRs have no additional cysteines as in the LEC-CAM family.
In 1988, Kotwal (Porter & Reid, 1978 Muller-Eberhard & Lepow, 1965; Kerr, 1980; Bhakdi & Tranum Janssen, 1983; Lundwall et al., 1981) . Table 1 lists the physical properties as well as the plasma concentration of C4. Synthesized in the liver as a single chain polypeptide of 1706 amino acids (Belt et al., 1984) it undergoes several modifications involving proteolytic excision of two intersubunit-linking peptides (Goldberger & Colten, 1980) , sulphation (Karp, 1983a) , glycosylation (Matthews et al., 1982) , and generation of a thiolester site in the a-chain (Karp, 1983b) . The proteolytic cleavage by Cls in the N-terminal part of the achain of C4 leads to the generation of the activation peptide C4a (8 kDa) and the activated component C4b (181 kDa). C4b contains at least two binding sites. One is unstable and responsible for the binding of C4b to antibody-antigen aggregates and to acceptor sites on cell surfaces (Porter & Reid, 1978 Muller-Eberhard & Lepow, 1965) . The other binding site of C4b is stable and specific for C2 (Kerr, 1980) . C2 bound to C4b will be cleaved by Cls, resulting in the C4b2a complex which acts as the C3 convertase (Kerr, 1980) . Cleavage of C4b by factor I and C4BP in the a'-chain of C4b leads to the generation of the intermediate product, C4b', after the first cleavage of the a'-chain, resulting in a 70 kDa and a 16 kDa a4-fragment of the a'-chain both still disulphide-linked to the other chains (see Fig. 5 ). The second cleavage results in the excision of C4d [45 kDa (a2)], and the generation of a third fragment [27 kDa (a2)], of the a'-chain still disulphide-linked to C4c . The C4BP binding site has been localized on the a'-chain of C4b and it has been demonstrated that this binding could be inhibited by monoclonal antibodies specific for the a'-chain (Hessing et al., 1990b) . The epitopes of these monoclonal antibodies were identified between the residues Ala738-Arg826 and it was concluded that the C4BP binding site is localized at the N-terminus of the a3-fragment of C4b (Hessing et al., 1990d) . As C4BP binds both to C4b and to the negatively charged heparin via its Nterminal 48 kDa chymotryptic tentacles (Hessing et al., 1990a) , which have been shown to contain basic residues between SCR 1 and 2 of the a-chains of C4BP (Chung et al., 1985a,b; Janatova et al., 1989) , a cluster of seven acidic amino acids between residues 744-752 in C4b might be important for binding.
The activation of C4 is accompanied by a conformational change. C4 treated with nitrogen nucleophiles, chaotropic reagents or frozen-thawed (i.e. C4b-like C4 or iC4) undergoes the same conformational alterations as a result of the cleavage of the internal thiolester bond in the a-chain in C4 after activation.
Both iC4 and soluble C4b are able to assemble the fluid-phase C3 convertase, are haemolytically inactive, form a complex with C4BP and are attacked by factor I Zabern & . Human C4 is very polymorphic (Mauff et al., 1983) , 1984) . C4A preferentially forms amide bonds with protein, while C4B binds more efficiently to hydroxyl groups of carbohydrate and to some extent protein (Isenman & Young, 1984; Law et al., 1984) . Little is known about the affinity of the interaction of the two isotypes with C4BP and if they are equally susceptible to cleavage by factor I.
BIOSYNTHESIS OF THE COMPLEMENT COMPONENTS C4BP, C4 AND THE VITAMIN K-DEPENDENT PROTEIN S
Protein S is synthesized and secreted by human hepatoma cell lines , human and bovine endothelial cells Stern et al., 1986a) , megakaryocytes (Ogura et al., 1987) and a human erythroleukemia cell line (Schwarz et al., 1985a) . In human platelets protein S is contained in the agranules and is released by thrombin stimulation (Schwarz et al., 1985b (Schwarz et al., , 1986 .
Human complement C4 and C4BP are synthesized in the liver, and Saeki et al. (1989) reported that the synthesis and secretion of C4BP by human hepatoma cells was enhanced by interleukin-6 and tumour necrosis factor, suggesting that C4BP is an acute phase protein. Funakoshi et al. (1988) established that also proline-rich protein (which may be identical to C4BP; see above) is an acute phase reactant and that the plasma concentration of proline-rich protein correlated with known acute phase reactants. Lappin & Whaley (1990) reported on the synthesis of C4BP by cultured human monocytes, which was increased after interferon 1991 stimulation. C4BP has not been detected in human endothelial cells or platelets.
CLINICAL PERSPECTIVES
The importance of protein S as an anticoagulant has been demonstrated by the identification of several patients with heterozygous protein S deficiency associated with recurrent venous thrombosis (Comp & Esmon, 1984; Schwarz et al., 1984; Broekmans et al., 1985; Bertina, 1985; Kamiya et al., 1986) or with abnormalities of bone mineral density (Pan et al., 1990) . The incidence of heterozygous protein S deficiency in patients with thrombotic disease is between 5 and 8% (Broekmans, 1985; Bertina, 1985; Gladson et al., 1985) . The disorder is probably inherited as an autosomal dominant trait (Schwarz et al., 1984; Broekmans et al., 1985; Bertina, 1985; Mannucci et al., 1986) . Recently, molecular alterations in the protein S genes have been reported in families exhibiting protein S deficiency (Ploos van Amstel et al., 1989a,b; Schwarz et al., 1989) . Also an acquired protein S deficiency may be a risk factor for the development of thromboembolic complications and may occur in the nephrotic syndrome (Vigano-D'Angelo et al., 1987) , in systemic lupus erythematosus (Friedman et al., 1987) , during oral anticoagulation (Weiss, 1987; D'Angelo et al., 1988) , during pregnancy (Comp et al., 1986; Rose et al., 1986; Malm et al., 1988a) , during oral contraception (Boerger et al., 1987; Huisveld et al., 1987; , in sickle cell anemia (Francis, 1988) , during chemotherapy for breast cancer (Rogers et al., 1988) , in liver disease and in disseminated intravascular coagulation (D'Angelo et al., 1988) .
There is little documentation of changes in C4BP levels in disease or trauma and so far no deficiency of C4BP has been reported. However, C4BP is hormonally regulated, with levels increasing slightly during pregnancy and in women using oral contraceptives (Comp et al., 1986; Boerger et al., 1987; Malm et al., 1988a; . Saeki et al. (1989) described a moderate increase of C4BP levels in patients with acute pneumonia during acute phase and Barnum & Dahlback (1990) found that C4BP is elevated in systemic lupus erythematosus. In addition, Kusunoki et al. (1989) reported glomerular deposition of C4BP in patients with idiopathic membranous glomerulonephritis. Low or undetectable levels of protein S-C4BP complexes have been found in term and preterm infants (Malm et al., 1988b; Schwarz et al., 1988; Maolic et al., 1988; .
A complete deficiency ofC4, albeit rare, is invariably correlated with severe immune complex disease and is often fatal (Hauptman et al., 1986) . Also the rather common partial deficiency in one of the isotypes of C4 is associated with an increased susceptibility to immune complex disease (Fielder et al., 1983; Rittner et al., 1984; Revielle et al., 1985; Howard et al., 1986) . Whether the C4 deficiency is causative or simply serves as a marker for a linked disease susceptibility gene is not known.
CONCLUDING REMARKS
There are remarkably few interactions known between the coagulation and complement cascades. Although experiments in vitro have indicated that complement components can be cleaved by coagulation enzymes and vice versa, and while these enzymic cleavages resemble activation in vivo, the physiological importance of these observations remains uncertain (Bennet et al., 1987) . In this review I have tried to provide some insights into recent developments in a unique link between coagulation and complement pathways, namely the interaction between C4, C4BP 
